Tuberous sclerosis natural history, complications and prognosis: Difference between revisions
Jump to navigation
Jump to search
Jose Loyola (talk | contribs) |
Jose Loyola (talk | contribs) |
||
| (One intermediate revision by the same user not shown) | |||
| Line 12: | Line 12: | ||
* Common complications of tuberous sclerosis include: | * Common complications of tuberous sclerosis include: | ||
**[[Blindness]] (due to retinal astrocytic hamartomas);<ref>Wan, | **[[Blindness]] (due to retinal astrocytic hamartomas);<ref name="pmid31417327">{{cite journal| author=Wan MJ, Chan KL, Jastrzembski BG, Ali A| title=Neuro-ophthalmological manifestations of tuberous sclerosis: current perspectives. | journal=Eye Brain | year= 2019 | volume= 11 | issue= | pages= 13-23 | pmid=31417327 | doi=10.2147/EB.S186306 | pmc=6592065 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=31417327 }}</ref> | ||
**[[Internal bleeding]] (due to ruptured [[Angiomyolipoma|angiomyolipomas]]); | **[[Internal bleeding]] (due to ruptured [[Angiomyolipoma|angiomyolipomas]]); | ||
**[[Renal-cell carcinomas]];<ref name="pmid170059523">{{cite journal| author=Crino PB, Nathanson KL, Henske EP| title=The tuberous sclerosis complex. | journal=N Engl J Med | year= 2006 | volume= 355 | issue= 13 | pages= 1345-56 | pmid=17005952 | doi=10.1056/NEJMra055323 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=17005952 }}</ref><ref name="pmid272262342">{{cite journal| author=Henske EP, Jóźwiak S, Kingswood JC, Sampson JR, Thiele EA| title=Tuberous sclerosis complex. | journal=Nat Rev Dis Primers | year= 2016 | volume= 2 | issue= | pages= 16035 | pmid=27226234 | doi=10.1038/nrdp.2016.35 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=27226234 }}</ref> | **[[Renal-cell carcinomas]];<ref name="pmid170059523">{{cite journal| author=Crino PB, Nathanson KL, Henske EP| title=The tuberous sclerosis complex. | journal=N Engl J Med | year= 2006 | volume= 355 | issue= 13 | pages= 1345-56 | pmid=17005952 | doi=10.1056/NEJMra055323 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=17005952 }}</ref><ref name="pmid272262342">{{cite journal| author=Henske EP, Jóźwiak S, Kingswood JC, Sampson JR, Thiele EA| title=Tuberous sclerosis complex. | journal=Nat Rev Dis Primers | year= 2016 | volume= 2 | issue= | pages= 16035 | pmid=27226234 | doi=10.1038/nrdp.2016.35 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=27226234 }}</ref> | ||
| Line 22: | Line 22: | ||
**[[Anxiety Disorder|Anxiety]]; | **[[Anxiety Disorder|Anxiety]]; | ||
**[[Autism]];<ref name="pmid170059523" /> | **[[Autism]];<ref name="pmid170059523" /> | ||
**[[Heart failure]] due to intracavitary cardiac [[rhabdomyomas]].<ref>Hinton RB, Prakash A, Romp RL, Krueger DA, Knilans TK | **[[Heart failure]] due to intracavitary cardiac [[rhabdomyomas]].<ref name="pmid25424575">{{cite journal| author=Hinton RB, Prakash A, Romp RL, Krueger DA, Knilans TK, International Tuberous Sclerosis Consensus Group| title=Cardiovascular manifestations of tuberous sclerosis complex and summary of the revised diagnostic criteria and surveillance and management recommendations from the International Tuberous Sclerosis Consensus Group. | journal=J Am Heart Assoc | year= 2014 | volume= 3 | issue= 6 | pages= e001493 | pmid=25424575 | doi=10.1161/JAHA.114.001493 | pmc=4338742 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=25424575 }}</ref> | ||
==Prognosis== | ==Prognosis== | ||
Latest revision as of 15:07, 20 July 2020
|
Tuberous sclerosis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Tuberous sclerosis natural history, complications and prognosis On the Web |
|
American Roentgen Ray Society Images of Tuberous sclerosis natural history, complications and prognosis |
|
FDA on Tuberous sclerosis natural history, complications and prognosis |
|
CDC on Tuberous sclerosis natural history, complications and prognosis |
|
Tuberous sclerosis natural history, complications and prognosis in the news |
|
Blogs on Tuberous sclerosis natural history, complications and prognosis |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: José Eduardo Riceto Loyola Junior, M.D.[2]
Overview
Tuberous sclerosis is a disease that presents with a wide spectrum of clinical manifestations. With appropriate medical care, most individuals can expect normal life expectancy.
Natural History
- Those individuals with mild symptoms generally do well and live long productive lives, while individuals with the more severe form may have serious disabilities.
- However, with appropriate medical care, most individuals with the disorder can look forward to normal life expectancy.
Complications
- Common complications of tuberous sclerosis include:
- Blindness (due to retinal astrocytic hamartomas);[1]
- Internal bleeding (due to ruptured angiomyolipomas);
- Renal-cell carcinomas;[2][3]
- Chronic kidney disease;[4]
- Lymphangiomyomatosis;
- Multifocal micronodular pneumocyte hyperplasia;[2]
- Epilepsy, including its more severe form: infantile spasms;
- Obstructive hydrocephalus due to subependymal giant cell astrocytomas;
- Anxiety;
- Autism;[2]
- Heart failure due to intracavitary cardiac rhabdomyomas.[5]
Prognosis
- The prognosis for individuals with TSC depends on the severity of symptoms, which range from mild skin abnormalities to varying degrees of learning disabilities and epilepsy to severe mental retardation, uncontrollable seizures, and kidney failure.
References
- ↑ Wan MJ, Chan KL, Jastrzembski BG, Ali A (2019). "Neuro-ophthalmological manifestations of tuberous sclerosis: current perspectives". Eye Brain. 11: 13–23. doi:10.2147/EB.S186306. PMC 6592065 Check
|pmc=value (help). PMID 31417327. - ↑ 2.0 2.1 2.2 Crino PB, Nathanson KL, Henske EP (2006). "The tuberous sclerosis complex". N Engl J Med. 355 (13): 1345–56. doi:10.1056/NEJMra055323. PMID 17005952.
- ↑ Henske EP, Jóźwiak S, Kingswood JC, Sampson JR, Thiele EA (2016). "Tuberous sclerosis complex". Nat Rev Dis Primers. 2: 16035. doi:10.1038/nrdp.2016.35. PMID 27226234.
- ↑ Song X, Liu Z, Cappell K, Gregory C, Said Q, Prestifilippo J; et al. (2017). "Natural history of patients with tuberous sclerosis complex related renal angiomyolipoma". Curr Med Res Opin. 33 (7): 1277–1282. doi:10.1080/03007995.2017.1313726. PMID 28358266.
- ↑ Hinton RB, Prakash A, Romp RL, Krueger DA, Knilans TK, International Tuberous Sclerosis Consensus Group (2014). "Cardiovascular manifestations of tuberous sclerosis complex and summary of the revised diagnostic criteria and surveillance and management recommendations from the International Tuberous Sclerosis Consensus Group". J Am Heart Assoc. 3 (6): e001493. doi:10.1161/JAHA.114.001493. PMC 4338742. PMID 25424575.